Decisional dilemmas in discontinuing prolonged disease-modifying treatment for multiple sclerosis
Butler M, Forte ML, Schwehr N, Carpenter A, Kane RL
Record ID 32015000565
English
Authors' objectives:
We conducted a systematic review to examine the long-term consequences of discontinuing disease-modifying treatment (DMT) for multiple sclerosis (MS) by examining the long-term benefits and harms, and the reasons for discontinuing treatment. We also examined the evidence for people's values, beliefs, and preferences regarding discontinuing DMT.
Authors' recommendations:
MS patients and providers have little information to guide decisions to discontinue DMT.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.effectivehealthcare.ahrq.gov/ehc/products/535/2076/multiple-sclerosis-report-150427.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Adult
- Cost Savings
- Cost-Benefit Analysis
- Disability Evaluation
- Drug Administration Schedule
- Drug Costs
- Medical Futility
- Middle Aged
- Practice Guidelines as Topic
- Rural Health Services
- Severity of Illness Index
- Surveys and Questionnaires
- Treatment Failure
- Urban Health Services
- Immunosuppressive Agents
- Ireland
- Multiple Sclerosis, Chronic Progressive
- Neurology
- Practice Patterns, Physicians'
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.